Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,830,139
  • Shares Outstanding, K 131,570
  • Annual Sales, $ 374,330 K
  • Annual Income, $ 111,820 K
  • 60-Month Beta 0.96
  • Price/Sales 4.92
  • Price/Cash Flow 15.17
  • Price/Book 2.54
Trade MOR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.94
  • Number of Estimates 1
  • High Estimate -0.94
  • Low Estimate -0.94
  • Prior Year -0.58
  • Growth Rate Est. (year over year) -62.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.21 +5.75%
on 07/28/21
19.83 -29.55%
on 07/06/21
-4.99 (-26.32%)
since 07/02/21
3-Month
13.21 +5.75%
on 07/28/21
24.19 -42.25%
on 05/03/21
-9.98 (-41.67%)
since 04/30/21
52-Week
13.21 +5.75%
on 07/28/21
34.99 -60.07%
on 08/05/20
-18.19 (-56.56%)
since 07/31/20

Most Recent Stories

More News
MorphoSys AG Reports Second Quarter and First Half 2021 Results

XNCR : 30.87 (+0.29%)
MOR : 13.97 (+0.43%)
MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014

MOR : 13.97 (+0.43%)
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will...

MOR : 13.97 (+0.43%)
MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution...

MOR : 13.97 (+0.43%)
RPRX : 37.21 (-2.59%)
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology

Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma

MOR : 13.97 (+0.43%)
CNST : 33.99 (+0.06%)
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals

MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust...

MOR : 13.97 (+0.43%)
CNST : 33.99 (+0.06%)
Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion

Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma....

NVS : 92.27 (-0.13%)
BMY : 68.02 (+0.22%)
INCY : 78.47 (+1.45%)
MOR : 13.97 (+0.43%)
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European UnionThe positive opinion from the CHMP is based...

MOR : 13.97 (+0.43%)
INCY : 78.47 (+1.45%)
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

--- The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL...

MOR : 13.97 (+0.43%)
INCY : 78.47 (+1.45%)
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals

PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation...

MOR : 13.97 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

3rd Resistance Point 14.60
2nd Resistance Point 14.33
1st Resistance Point 14.15
Last Price 13.97
1st Support Level 13.70
2nd Support Level 13.43
3rd Support Level 13.25

See More

52-Week High 34.99
Fibonacci 61.8% 26.67
Fibonacci 50% 24.10
Fibonacci 38.2% 21.53
Last Price 13.97
52-Week Low 13.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar